CASE REPORT article

Front. Oncol., 23 May 2023

Sec. Neuro-Oncology and Neurosurgical Oncology

Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1090615

Case Report: Paraganglioma in the sellar region: longitudinal observation and surgical outcome

  • 1. Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, China

  • 2. Center for Precision Neurosurgery and Oncology of Peking University Health Science Center, Peking University, Beijing, China

  • 3. Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing, China

  • 4. Department of Neurosurgery, Inspired Spine Health, Burnsville, MN, United States

Article metrics

View details

4

Citations

2,7k

Views

1,2k

Downloads

Abstract

Background:

Paraganglioma in the sellar region is an extremely rare entity, with a limited number of cases reported in the literature. Due to the paucity of clinical evidence, the diagnosis and treatment of paragangliomas in the sellar region remain challenging. Herein, we reported a case of sellar paraganglioma with parasellar and suprasellar extension. Particularly, the dynamic evolution of this benign tumor within a 7-year longitudinal observation was presented. Additionally, the relevant literature regarding sellar paraganglioma was comprehensively reviewed.

Case description:

A 70-year-old woman presented with progressive visual deterioration and headache. Brain magnetic resonance imaging demonstrated a mass in the sellar region with parasellar and suprasellar extension. The patient refused surgical treatment. Seven years later, brain magnetic resonance imaging showed the lesion significantly progressed. Neurological examination revealed bilateral tubular contraction of visual fields. Laboratory examinations showed endocrine hormone levels were normal. Surgical decompression was performed via a subfrontal approach, and subtotal resection was achieved. Histopathological examination confirmed a diagnosis of paraganglioma. Postoperatively, she developed hydrocephalus, and ventriculoperitoneal shunting was performed. Eight months later, cranial CT showed no recurrence of the residual tumor, and the hydrocephalus had been relieved.

Conclusion:

Paraganglioma occurring in the sellar region is rare, and the preoperative differential diagnosis is difficult. Owing to the infiltration to the cavernous sinus and internal carotid, complete surgical resection is usually impracticable. There has been no consensus regarding postoperative adjuvant radiochemotherapy for the tumor residue. In-situ recurrence and metastasis have been reported in the literature, and close follow-up is warranted.

Introduction

Paragangliomas refer to benign neuroendocrine neoplasms originating from paraganglionic tissue, which are derived from neural crest progenitor cells. Except for the adrenal medulla, paragangliomas predominantly arise in the head and neck region, most commonly involving the carotid bodies, the jugular glomus, and the vagal bodies (1, 2). According to the literature, extra-adrenal paragangliomas account for only 10% to 15% of all paragangliomas (3); paragangliomas affecting the central nervous system are particularly rare, comprising approximately 0.6% of all head and neck neoplasms (4). Although paragangliomas are generally considered to be indolent entities corresponding histologically to World Health Organization (WHO) grade I (5), a high recurrence rate following surgical resection (10% for paragangliomas of carotid body and 50% to 60% for those occurring in other sites) and even metastasis (~10%) have been reported (6). Previously, we reported a consecutive surgical series of 19 patients with pathologically diagnosed spinal paragangliomas, in which we noted a considerable risk of in-situ recurrence Sellar paragangliomas are extremely unusual as paraganglia do not normally exist in this region, which has been only reported in very limited cases (7–36). This may be secondary to the persistence of paraganglionic tissue caused by deficient involution during early life. In this study, we presented a case of sellar paraganglioma with parasellar and suprasellar extension. Particularly, the dynamic evolution of this benign tumor within a 7-year longitudinal observation was presented. Additionally, the relevant literature regarding sellar paraganglioma was comprehensively reviewed.

Case description

History and clinicoradiological evaluations

A 70-year-old woman presented with a 3-year history of visual deterioration and headache. Physical examination revealed binocular severe visual disturbance. Brain magnetic resonance imaging (MRI) was requested, yielding a space-occupying lesion in the sellar region with right parasellar and suprasellar extension (Figure 1). The mass was irregular in shape displaying isointensity on T1-weighted imaging and heterogenous signals on T2-weighted imaging, and contrast enhancement was notable after the administration of gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA). Surgical resection of the lesion via a subfrontal approach was recommended, but the patient refused it considering the advanced age and mild symptoms.

Figure 1

During the following years, the visual field defect was progressively aggravated. The latest brain MRI after a 7-year conservative observation demonstrated the lesion significantly progressed (Figure 2), and the patient was readmitted. Ophthalmologic examination showed bilateral visual field defects and pathologic myopia with posterior staphyloma and tigroid fundus (Figure 3). Other cranial nerves were normal, and there were no sensorimotor dysfunctions. Laboratory examinations showed endocrine hormone levels (including prolactin [PRL], growth hormone [GH], follicle stimulating hormone [FSH], luteinizing hormone [LH], adrenocorticotropic hormone [ACTH], and thyroid hormones) were all within normal limits. Cranial computed tomography (CT) and MRI demonstrated a giant lobulated sellar mass with parasellar and suprasellar extension, and the optic chiasm was remarkably displaced; the lesion was isointense on T1-weighted imaging and heterogeneously hyperintense on T2-weighted imaging, with remarkable enhancement after administration of contrast medium (Figures 2A-G). CT angiography did not identify any significant vascular aberrance (Figure 2H).

Figure 2

Figure 3

Surgical treatment

Preoperatively, a diagnosis of nonfunctional pituitary adenoma was suspected. As the main body of the lesion extended to the suprasellar and parasellar areas, the transnasal-sphenoidal approach may be difficult to achieve complete tumor resection. The patient underwent a surgical decompression via a subfrontal approach. Intraoperatively, the tumor was found to be rubbery with an abundant blood supply. The tumor tissue was closely attached to the internal carotid artery and cavernous sinus, and subtotal resection was eventually achieved.

Histopathological examination

Histopathological sections revealed a tumor with a lobulated pattern and cellular nests surrounded by vascular fibrous septa (Figure 4). The irregular and lobulated clusters of cuboidal cells were consistent with the morphological characteristics of paraganglioma (Zellballen pattern). Immunohistochemical stains showed the tumor cells were strongly positive for synaptophysin (SYN), chromogranin A (CgA), and microtubule-associated protein 2 (MAP-2), but negative for glial fibrillary acidic protein (GFAP), S100 protein, epithelial membrane antigen (EMA), cytokeratin (CK), CD68, and neuronal nuclear antigen (NeuN). Additionally, the tumor cells showed no immunoreactivity against pituitary cell-lineage transcription factors (T-PIT, PIT-1, SF-1), thyroid transcription factor 1 (TTF-1), or endocrine markers (PRL, GH, thyroid stimulating hormone [TSH], ACTH, FSH, LH). The Ki-67 proliferation index was <5%. A diagnosis of paraganglioma was made.

Figure 4

Postoperative course

Postoperative CT confirmed the tumor was subtotally removed, and the tumor cavity was filled with hemostatic material (Figure 5A). The patient’s visual function showed no significant improvement. One month after the operation, she developed gait disturbance and urinary incontinence. Repeated cranial CT showed ventricle dilation with interstitial edema (Figure 5B). A secondary hydrocephalus was diagnosed and a ventriculoperitoneal shunting was performed (Figure 5C). A week postoperatively, the neurological deficiencies were partially improved, and CT showed the ventricles shrank (Figure 5D). Eight months postoperatively, cranial CT showed no recurrence of the residual tumor, and the hydrocephalus had been relieved (Figures 5E, F). However, she got pneumonia two months later and succumbed to respiratory failure.

Figure 5

Literature review

We conducted a literature review to identify articles on sellar paragangliomas published up to November 1, 2022. We performed a systematic search of the PubMed and Embase databases using the terms “paraganglioma” and “sellar”. A total of 30 publications were retrieved, and all of them are case reports.

There were 13 females and 22 males (including our current case), with a female-to-male ratio of 1:1.69. The average age was 46.9 ± 22.5 (range, 13~84 years). The most common onset symptoms were visual deficits (68.6%) and headache (65.7%). All the patients underwent surgical treatment, and no complete resection was described. Postoperative adjuvant radiation was administered for controlling the tumor residue in 45.7% of all cases (16 of 35 cases), with a dosage of 40~50 Gy (20~28 fractions). Follow-up data were available in 23 cases; after an average follow-up period of 21.5 ± 28.8 months, two patients experienced in-situ recurrence, and metastasis was noted in two other cases. Demographic and clinical profiles were summarized in Table 1. Radiological characteristics were presented in Table 2.

Table 1

Authors/yearCase
No.		GenderAge (years)Onset SymptomsDurationTreatmentFollow-up periodOutcome
Ho et al./1982 (7)1Male65Headache and VDN.A.Surgery and RT4 monthsStable
Steel et al./1993 (8)2Female44Headache3 yearsSurgery and RT1 yearStable
3Female41Headache, nausea and vomitingN.A.Surgery and RT (50Gy)1 yearStable
Scheithauer et al./1996 (9)4Male14Headache3 monthsSurgery and RT
(45 Gy/28 fractions)		7 yearsRecurrence
Noble et al./1997 (10)5Male71VDN.A.SurgeryN.A.N.A.
6Male14headacheN.A.SurgeryN.A.N.A.
Mokry et al./1998 (11)7Female76VD6 monthsSurgeryN.A.N.A.
Del Basso De Caro et al./
1998 (12)		8Male84MD2 monthsSurgery1 yearStable
Sambaziotis et al./1999 (13)9Male54VDN.A.SurgeryN.A.N.A.
Salame et al./2001 (14)10Female48Headache and VDN.A.SurgeryN.A.N.A.
Laquis et al./2001 (15)11Female15Headache, exophthalmos and VDN.A.Surgery and RTN.A.N.A.
Hertel et al./2003 (16)12Female51Headache and facioplegiaN.A.Surgery and RT3 monthsStable
Arkha et al./2003 (17)13Female58VD and exophthalmosN.A.SurgeryN.A.N.A.
Riopel et al./2004 (18)14Male66Headache and VDN.A.SurgeryN.A.N.A.
Zorlu et al./2005 (19)15Male37VD1 yearSurgery20 monthsTumor shrinkage
Naggara et al./2005 (20)16Male47MD and VDN.A.SurgeryN.A.N.A.
Boari et al./2006 (21)17Male52HeadacheN.A.Surgery3 yearsStable
Peltier et al./2007 (22)18Female51Headache, VD and oculomotor palsyN.A.Surgery and RT (45Gy)N.A.N.A.
Sinha et al./2008 (23)19Male18Headache and VD2 monthsSurgery and RT4 monthsMetastasis
Ozum et al./2008 (24)20Male70HeadacheN.A.Surgery and RT (50Gy)N.A.N.A.
Lu et al./2009 (25)21Male81Headache and VD3 weeksSurgery4 monthsDeath
Haresh et al./2009 (26)22Male17Headache and VD2 monthsSurgery and RT
(50 Gy/25 fractions)		4 monthsMetastasis
Albert et al./2011 (27)23Male63Exophthalmos5 yearsSurgery and RT6 weeksStable
Do Nascimento et al./2012 (28)24Female33Headache and VDN.A.SurgeryN.A.N.A.
Chaudhry et al./2013 (29)25Male44Headache and VD1 yearSurgery20 monthsTumor shrinkage
Karlekar et al./2018 (30)26Male19VDN.A.Surgery and RT1 yearStable
Lyne et al./2019 (31)27Female73Headache and VDN.A.Surgery6 monthsStable
Tan et al./2019 (32)28Female40VD and headache1 monthSurgery and RT
(50 Gy/28 fractions)		8 monthsRecurrence
29Female59SIADHN.A.Surgery3 monthsStable
Schueth et al./2020 (33)30Male81VD and MD2 yearsSurgery2.5 yearsStable
Vasoya et al./2020 (34)31Male13Headache and VD6 monthsSurgery and RT
(50 Gy,25 fractions)		4 yearsTumor shrinkage
32Male20VD3 monthsSurgery and RT
(40 Gy,20 fractions)		8 monthsTumor shrinkage
Stojanoski et al./2021 (35)33Male31Headache and nausea2 monthsSurgery and RT
(48 Gy,24 fractions)		10 yearsRecurrence and metastasis
Ghaisas et al./2022 (36)34Male20Headache and VD2 yearsSurgery and RT
(40 Gy/20 fractions)		3 yearsTumor shrinkage
Present Case35Female70Headache and VD3 yearsSurgery8 monthsStable

Demographic and clinical features of paragangliomas in the sellar region.

VD, visual deficit; MD, mental disorder; SIADH, syndrome of inappropriate antidiuretic hormone secretion; N.A., not available; RT, radiation therapy.

Table 2

Authors/yearCase
No.		T1-weighted imagingT2-weighted imagingGd-DTPAInvolvementBone Destruction
Cavernous SinusInternal Carotid ArteryOptic PathwayThe Third Ventricle
Ho et al./19821N.A.N.A.N.A.RightN.A.N.A.N.A.N.A.
Steel et al./19932IsointenseN.A.EnhancementLeftEncasementN.A.N.A.N.A.
3N.A.N.A.EnhancementBilateralEncasementN.A.N.A.N.A.
Scheithauer et al/19964N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.
Noble et al./19975IsointenseHyperintenseEnhancementBilateralEncasementYesYesYes
6N.A.N.A.EnhancementRightEncasementYesNoN.A.
Mokry et al./19987IsointenseHyperintenseEnhancementNoNoYesNoNo
Del Basso De Caro et al./19988N.A.N.A.N.A.LeftN.A.N.A.YesN.A.
Sambaziotis et al./19999N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.
Salame et al./200110IsointenseHyperintenseEnhancementLeftEncasementYesYesNo
Laquis et al./200111N.A.N.A.EnhancementBilateralEncasementYesNoYes
Hertel et al./200312IsointenseHyperintenseEnhancementBilateralInvolvementYesYesYes
Arkha et al./200313N.A.N.A.N.A.N.A.N.A.N.A.N.A.N.A.
Riopel et al./200414IsointenseN.A.EnhancementNoNoNoNoYes
Zorlu et al./200515N.A.N.A.EnhancementN.A.N.A.N.A.N.A.N.A.
Naggara et al./200516IsointenseHyperintenseEnhancementNoNoYesYesNo
Boari et al./200617N.A.N.A.EnhancementNoNoYesNoNo
Peltier et al./200718N.A.N.A.EnhancementLeftEncasementN.A.N.A.N.A.
Sinha et al., 200819N.A.N.A.EnhancementN.A.N.A.NoNoNo
Ozum et al./200820N.A.N.A.N.A.BilateralEncasementNoNoYes
Lu et al./200921N.A.HyperintenseEnhancementRightEncasementYesYesNo
Haresh et al./200922IsointenseHyperintenseEnhancementBilateralEncasementYesYesNo
Albert et al./201123N.A.HyperintenseN.A.LeftEncasementN.A.N.A.N.A.
Do Nascimento et al./201224N.A.N.A.EnhancementBilateralEncasementYesYesNo
Chaudhry et al./201325IsointenseHyperintenseEnhancementBilateralEncasementYesNoYes
Karlekar et al./201826N.A.N.A.EnhancementN.A.N.A.YesYesNo
Lyne et al./201927N.A.N.A.N.A.BilateralEncasementYesNoYes
Tan et al./201928N.A.N.A.EnhancementRightEncasementYesNoNo
29N.A.N.A.EnhancementBilateralEncasementYesNoNo
Schueth et al./202030N.A.HyperintenseN.A.NoNoNoNoNo
Vasoya et al./202031N.A.N.A.EnhancementBilateralEncasementYesYesNo
32N.A.N.A.EnhancementBilateralEncasementYesYesNo
Stojanoski et al./202133IsointenseHyperintenseEnhancementBilateralEncasementNoNoNo
Ghaisas et al./202234N.A.N.A.EnhancementN.A.N.A.YesYesNo
Present Case35IsointenseHeterogeneousEnhancementRightEncasementYesYesNo

Radiological characteristics of paragangliomas in the sellar region.

N.A., not available.

Discussion

Paragangliomas are relatively rare tumors that develop from the paraganglia of the autonomic nervous system. Because the sellar region lacks autonomic nervous tissue and there are no paraganglia, the derivation and etiology of sellar paragangliomas remain a mystery. Regarding its origin, there are two hypotheses: 1) the ‘embryonic remnants’ theory, proposing that paraganglioma may arise from the embryonic paraganglionic cells trapped around the pituitary; or 2) the ‘ectopic migration’ theory, holding that paraganglioma may originate from paraganglionic cells abnormally migrated across the tympanic or ciliary branches of the glossopharyngeal nerve to the cavernous sinus (8, 20). In this study, we found the majority of reported cases showed involvement of the cavernous sinus, which seems to support the latter view. Additionally, the most common onset symptom was visual decline rather than abnormal pituitary endocrine function, highly implying paraganglioma is an extra-pituitary lesion. In our current case, a longitudinal conservative observation demonstrated remarkable tumor growth. At the early stage, the tumor invaded the right cavernous sinus and encased the right internal carotid artery, while no osseous destruction or pituitary dysfunctions were noted. These clinicoradiological features prompted the cavernous sinus origin of sellar paragangliomas.

Preoperative diagnosis of sellar paragangliomas is extremely challenging, and differential diagnoses mainly include pituitary adenomas, meningiomas, craniopharyngiomas, germinomas, and Rathke cleft cysts. In most cases, sellar paragangliomas tend to be misdiagnosed as nonfunctional pituitary adenomas. The following potential characteristics may assist the diagnosis: 1) despite the giant size of the tumor, the patient’s endocrinal functions are usually normal; 2) just like the “salt and pepper” appearance on T2-weighted imaging that is frequently seen in peripheral paragangliomas, the high vascularization leads to heterogeneous intensity on T2-weighted imaging in sellar paragangliomas. Some scholars also proposed that functional imaging, such as 18F-DOPA positron emission tomography, may help confirm the neuroendocrine nature of tumors with high specificity (37, 38). Moreover, the imaging also shows additional advantages in diagnosing multifocality (co-existing paragangliomas in the rest of the body) and/or distant metastases (38, 39).

The most common symptom, visual deterioration, is caused by the tumor compression to the optic chiasma, and thus surgical resection of the tumor is the most effective treatment. The optional surgical strategies include the subfrontal approach, the transpterional approach, and transnasal-sphenoidal operations. In some cases, sellar paragangliomas are highly vascularized, and preoperative angiography may provide essential information for the identification of tumor blood supply. When a definitive supplying artery can be identified, preoperative endovascular embolization may significantly reduce the risk of intraoperative bleeding. In our case, the tumor was moderately enhanced after the administration of contrast medium and computed tomographic angiography showed no vascular aberrance, and thus endovascular embolization was not performed. Sellar paragangliomas are usually lobulated, and the cavernous sinus and internal carotid artery are always involved; therefore, intraoperative complete resection of the tumor may be extraordinarily difficult. For controlling the tumor residue, postoperative radiotherapy showed potential efficacies. Chemotherapy has not yet been reported for sellar paragangliomas.

The surgical outcomes of sellar paragangliomas varied distinctly. In most cases, surgery with or without radiation therapy leads to residual stability or even tumor shrinkage. Metastasis can also occur in a few cases, and close follow-up is indispensable.

Conclusions

Paragangliomas occurring in the sellar region are rare, and preoperative differential diagnosis is difficult. Complete surgical resection of the tumor is usually impracticable, and postoperative adjuvant radiotherapy can be considered for the tumor residue. In-situ recurrence and metastasis have been reported in the literature, and close follow-up should be highlighted.

Statements

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

Written informed consent was obtained from the individual legal guardian for the publication of any potentially identifiable images or data included in this article.

Author contributions

Conception and design: CY. Acquisition of data: YW, XZ, WL, and QM. Analysis and interpretation of data: XY, QM, JS, and VHN. Drafting and critically revising the article: YW, XY, and CY. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Natural Science Foundation of China (81901202 to CY; 82002883 to XY), Beijing Natural Science Foundation (7222217 to CY), the Capital Health Research and Development of Special (2022-4-40918 to CY), AO Spine Research Start-up Grant (AOS-Startup-21-016 to CY), Clinical Medicine Plus X-Young Scholars Project, Peking University, the Fundamental Research Funds for the Central Universities (PKU2021LCXQ007 to CY), and the priming scientific research foundation for the junior researcher in Beijing Tongren Hospital, Capital Medical University (2020-YJJ-ZZL-017 to XY).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    WelanderJSoderkvistPGimmO. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer (2011) 18(6):R253–76. doi: 10.1530/ERC-11-0170

  • 2

    KliewerKECochranAJ. A review of the histology, ultrastructure, immunohistology, and molecular biology of extra-adrenal paragangliomas. Arch Pathol Lab Med (1989) 113(11):1209–18.

  • 3

    BrahmbhattPPatelPSaleemANarayanRYoungM. Retroperitoneal paraganglioma presenting as a chest pain: a case report. Case Rep Oncol Med (2013) 2013:329472. doi: 10.1155/2013/329472

  • 4

    ChangHSilvaMATorresAAWengJde Lima GuidoLPVelez-TorresJet al. A carcinoid tumor of the middle ear masquerading as a glomus tympanicum presenting with temporal lobe hemorrhage in a 70-year-old woman: case report and review of the literature. Neurochirurgie (2022) 68(6):654–60. doi: 10.1016/j.neuchi.2022.07.008

  • 5

    YangCLiGFangJWuLYangTDengXet al. Clinical characteristics and surgical outcomes of primary spinal paragangliomas. J Neurooncol (2015) 122(3):539–47. doi: 10.1007/s11060-015-1742-0

  • 6

    ReithmeierTGumprechtHStolzleALumentaCB. Intracerebral paraganglioma. Acta Neurochir (Wien) (2000) 142(9):1063–6. doi: 10.1007/s007010070064

  • 7

    HoKCMeyerGGarancisJHannaJ. Chemodectoma involving the cavernous sinus and semilunar ganglion. Hum Pathol (1982) 13(10):942–3. doi: 10.1016/S0046-8177(82)80058-0

  • 8

    SteelTRDaileyATBornDBergerMSMaybergMR. Paragangliomas of the sellar region: report of two cases. Neurosurgery (1993) 32(5):844–7. doi: 10.1227/00006123-199305000-00021

  • 9

    ScheithauerBWParameswaranABurdickB. Intrasellar paraganglioma: report of a case in a sibship of von hippel-lindau disease. Neurosurgery (1996) 38(2):395–9. doi: 10.1097/00006123-199602000-00034

  • 10

    NobleERSmokerWRGhatakNR. Atypical skull base paragangliomas. AJNR Am J Neuroradiol (1997) 18(5):986–90.

  • 11

    MokryMKleinertRClariciGObermayer-PietschB. Primary paraganglioma simulating pituitary macroadenoma: a case report and review of the literature. Neuroradiology (1998) 40(4):233–7. doi: 10.1007/s002340050573

  • 12

    Del Basso De CaroMLSicilianoACappabiancaPAlfieriAde DivitiisE. Intrasellar paraganglioma with suprasellar extension: case report. Tumori (1998) 84(3):408–11. doi: 10.1177/030089169808400319

  • 13

    SambaziotisDKontogeorgosGKovacsKHorvathELevedisA. Intrasellar paraganglioma presenting as nonfunctioning pituitary adenoma. Arch Pathol Lab Med (1999) 123(5):429–32. doi: 10.5858/1999-123-0429-IPPANP

  • 14

    SalameKOuaknineGEYossipovJRochkindS. Paraganglioma of the pituitary fossa: diagnosis and management. J Neurooncol (2001) 54(1):49–52. doi: 10.1023/A:1012535230135

  • 15

    LaquisSJVickVHaikBGFlemingJCWilsonMW. Intracranial paraganglioma (glomus tumor) with orbital extension. Ophthalmic Plast Reconstr Surg (2001) 17(6):458–61. doi: 10.1097/00002341-200111000-00015

  • 16

    HertelFBettagMMorsdorfMFeidenW. Paragangliomas of the parasellar region. Neurosurg Rev (2003) 26(3):210–4. doi: 10.1007/s10143-003-0266-9

  • 17

    ArkhaYBoutarbouchMLamalmiNHalefadlSLaamartiADerrazSet al. Paraganglioma of the latero-sellar area. case report. Neurochirurgie (2003) 49(5):540–4.

  • 18

    RiopelCCourvillePFabreBCallonnecFBologniniBMarieJPet al. Parasellar paraganglioma: a case report. Ann Pathol (2004) 24(1):62–7. doi: 10.1016/S0242-6498(04)93903-X

  • 19

    ZorluFSelekUUlgerSDonmezTErdenE. Paraganglioma in sella. J Neurooncol (2005) 73(3):265–7. doi: 10.1007/s11060-004-5673-4

  • 20

    NaggaraOVarletPPagePOppenheimCMederJF. Suprasellar paraganglioma: a case report and review of the literature. Neuroradiology (2005) 47(10):753–7. doi: 10.1007/s00234-005-1422-4

  • 21

    BoariNLosaMMortiniPSniderSTerreniMRGiovanelliM. Intrasellar paraganglioma: a case report and review of the literature. Acta Neurochir (Wien) (2006) 148(12):1311–4. doi: 10.1007/s00701-006-0895-1

  • 22

    PeltierJFichtenALefrancMGrunewaldPTheluFToussaintPet al. Paraganglioma of the cavernous sinus. case report. Neurochirurgie (2007) 53(5):391–4. doi: 10.1016/j.neuchi.2007.06.006

  • 23

    SinhaSSharmaMCSharmaBS. Malignant paraganglioma of the sellar region mimicking a pituitary macroadenoma. J Clin Neurosci (2008) 15(8):937–9. doi: 10.1016/j.jocn.2007.03.029

  • 24

    OzumUEgilmezRYildirimA. Paraganglioma in pituitary fossa. Neuropathology (2008) 28(5):547–50. doi: 10.1111/j.1440-1789.2008.00885.x

  • 25

    LuJQKhalilMHuWSutherlandGRClarkAW. Tumor-to-tumor metastasis: esophageal carcinoma metastatic to an intracranial paraganglioma. J Neurosurg (2009) 110(4):744–8. doi: 10.3171/2008.9.JNS08397

  • 26

    HareshKPPrabhakarRAnand RajanKDSharmaDNJulkaPKRathGK. A rare case of paraganglioma of the sella with bone metastases. Pituitary (2009) 12(3):276–9. doi: 10.1007/s11102-008-0099-1

  • 27

    AlbertARamirezJACodereFPetreccaK. Sellar paraganglioma: a unique route to a rare destination case report and literature review. Clin Neurol Neurosurg (2011) 113(8):675–7. doi: 10.1016/j.clineuro.2011.04.002

  • 28

    do NascimentoAMaranhaLACorredatoRAAraujoJCBleggi-TorresLF. 33 year-old woman with a large sellar tumor. Brain Pathol (2012) 22(6):869–70. doi: 10.1111/j.1750-3639.2012.00640.x

  • 29

    ChaudhryNSAhmadFBliedenCMorcosJJ. Suprasellar and sellar paraganglioma presenting as a nonfunctioning pituitary macroadenoma. J Clin Neurosci (2013) 20(11):1615–8. doi: 10.1016/j.jocn.2013.02.004

  • 30

    KarlekarMKumarSJadhavSLilaABandgarTShahN. Sellar paraganglioma. Clin Nucl Med (2018) 43(8):591–2. doi: 10.1097/RLU.0000000000002157

  • 31

    LyneSBPolsterSPFidaiSPytelPYaminiB. Primary sellar paraganglioma: case report with literature review and immunohistochemistry resource. World Neurosurg (2019) 125:32–6. doi: 10.1016/j.wneu.2019.01.094

  • 32

    TanCLPangYHLimKHCSeinLCoddPJMcLendonRE. Two extraordinary sellar neuronal tumors: literature review and comparison of clinicopathologic features. Am J Clin Pathol (2019) 151(3):241–54. doi: 10.1093/ajcp/aqy155

  • 33

    SchuethEAMartinezDCKulwinCGBonninJMPaynerTDTingJY. Recurrent primary intrasellar paraganglioma. Case Rep Otolaryngol (2020) 2020:2580160. doi: 10.1155/2020/2580160

  • 34

    VasoyaPAryanSThakarSSivarajuLGhosalNHegdeAS. Sellar-suprasellar paraganglioma: report of 2 cases and review of literature. World Neurosurg (2020) 140:293–300. doi: 10.1016/j.wneu.2020.04.157

  • 35

    StojanoskiSBoldtHBKozicDPatocsAKorbonitsMMedic-StojanoskaMet al. Case report: malignant primary sellar paraganglioma with unusual genetic and imaging features. Front Oncol (2021) 11:739255. doi: 10.3389/fonc.2021.739255

  • 36

    GhaisasSRaoKSPreethiARaniPK. Suprasellar paraganglioma in a clinical setting of von hippel-lindau syndrome. BMJ Case Rep (2022) 15(3):e245907. doi: 10.1136/bcr-2021-245907

  • 37

    TaiebDKaliskiABoedekerCCMartucciVFojoTAdlerJRJr.et al. Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev (2014) 35(5):795–819. doi: 10.1210/er.2014-1026

  • 38

    TimmersHJTaiebDPacakK. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res (2012) 44(5):367–72. doi: 10.1055/s-0031-1299712

  • 39

    ArchierAVaroquauxAGarriguePMontavaMGuerinCGabrielSet al. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging (2016) 43(7):1248–57. doi: 10.1007/s00259-015-3268-2

Summary

Keywords

paraganglioma, sellar, extra-adrenal, surgical treatment, case report

Citation

Wang Y, Yang X, Ma Q, Nicholas VH-L, Sun J, Zhao X, Liu W and Yang C (2023) Case Report: Paraganglioma in the sellar region: longitudinal observation and surgical outcome. Front. Oncol. 13:1090615. doi: 10.3389/fonc.2023.1090615

Received

05 November 2022

Accepted

05 May 2023

Published

23 May 2023

Volume

13 - 2023

Edited by

Marcos Vinicius Calfat Maldaun, Hospital Sirio Libanes, Brazil

Reviewed by

Li Cai, CHI St. Vincent, United States; Cleiton Formentin, State University of Campinas, Brazil

Updates

Copyright

© 2023 Wang, Yang, Ma, Nicholas, Sun, Zhao, Liu and Yang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Chenlong Yang,

†These authors have contributed equally to this work and share first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Share on WeChat

Scan with WeChat to share this article

Article metrics